Lymphangiogenesis as a Prognostic Marker in Breast Cancer Using D2-40 as Lymphatic Endothelial Marker—A Preliminary Study


We studied tumour lymphangiogenesis and lymphatic invasion using D2-40 endothelial marker in 35 breast cancer patients treated by primary surgery and correlated it with various clinico-pathological prognostic parameters. Lymphangiogenesis was quantified using lymphatic micro vessel density (LMVD) by counting the immunostained lymphatic microvessels at 200X. The mean age was 45.97±12.09 years (range 30-80 years). LMVD ranged from 5/hpf to 56/hpf with a mean score of 13.4±10.8 and median of 9. The median value of 9 was taken to classify patients into a low or high LMVD. LMVD correlated significantly with tumour size (p=0.003), histological grade (p=0.046), lymph node status (p=0.030). There was no significant correlation of LMVD with stage, estrogen receptor, progesterone receptor or HER2/neu immunoreactivity. Lymphovascular invasion on D2-40 staining [LVI-D40] was found in 13 (37.1%) cases compared to 6 cases (17.1%) on H & E staining showing a poor agreement (k=0.244). LVI correlated significantly with lymph node status (p=0.011). There was a strong association between tumour size (p=0.142), histological grade (p=0.066) though the correlation was not statistically significant. No correlation was found with stage, estrogen receptor, progesterone receptor or HER2/neu immunoreactivity. The mean LMVD in LVI positive patients was higher (22.85±13.29) as compared to LVI negative patients (7.95±2.05) and this was statistically significant (p=0.001). Increased D2-40 detected LMVD and LVI correlated with poor prognostic parameters.

Share and Cite:

M. A. Ansari, V. Pandey, V. Srivastava, M. Kumar, R. Mishra and A. Kumar, "Lymphangiogenesis as a Prognostic Marker in Breast Cancer Using D2-40 as Lymphatic Endothelial Marker—A Preliminary Study," Journal of Cancer Therapy, Vol. 3 No. 5A, 2012, pp. 814-821. doi: 10.4236/jct.2012.325103.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] E. R. Fisher, et al., “Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17: Intraductal Carcinoma (Ductal Carcinoma in Situ),” Cancer, Vol. 75, No. 6, 1995, pp. 1310-1319. doi:10.1002/1097-0142(19950315)75:6<1310::AID-CNCR2820750613>3.0.CO;2-G
[2] P. A. Kyzas, et al., “Evidence for Lymphangiogenesis and Its Prognostic Implications in Head and Neck Squamous Cell Carcinoma,” Journal of Pathology, Vol. 206, No. 2, 2005, pp. 170-177. doi:10.1002/path.1776
[3] K. Schmid, et al., “Prognostic Value of Lymphatic and Blood Vessel Invasion in Neuroendocrine Tumours of the Lung,” The American Journal of Surgical Pathology, Vol. 29, 2005, pp. 324-328. doi:10.1097/01.pas.0000149706.74216.b6
[4] P. Bono, et al., “High LYVE-1-Positive Lymphatic Vessel Numbers Are Associated with Poor Outcome in Breast Cancer,” Clinical Cancer Research, Vol. 10, No. 21, 2004, pp. 7144-7149. doi:10.1158/1078-0432.CCR-03-0826
[5] C. S. M. Williams, et al., “Absence of Lymphangiogenesis and Intratumoural Lymph Vessels in Human Metastatic Breast Cancer,” The Journal of Pathology, Vol. 200, 2003, pp. 195-206. doi:10.1002/path.1343
[6] H. J. Kahn, et al., “Monoclonal Antibody D2-40, a New Marker of Lymphatic Endothelium, Reacts with Kaposi’s Sarcoma and a Subset of Angiosarcomas,” Modern Pathology, Vol. 15, No. 4, 2002, pp. 434-440. doi:10.1038/modpathol.3880543
[7] N. Weidner, et al., “Tumour Angiogenesis and Metastasis—Correlation in Invasive Breast Carcinoma,” The New England Journal of Medicine, Vol. 324, No. 1, 1991, pp. 1-8. doi:10.1056/NEJM199101033240101
[8] R. G. C. Dumitrescu, “Understanding Breast Cancer Risk Where Do We Stand in 2005?” Journal of Cellular and Molecular Medicine, Vol. 9, No. 1, 2005, pp. 208-221. doi:10.1111/j.1582-4934.2005.tb00350.x
[9] A. J. Leu, et al., “Absence of Functional Lymphatics within a Murine Sarcoma: A Molecular and Functional Evaluation,” Cancer Research, Vol. 60, No. 16, 2000, pp. 4324-4327.
[10] M. Skobe, et al., “Induction of Tumour Lymphangiogenesis by VEGF-C Promotes Breast Cancer Metastasis,” Nature Medicine, Vol. 7, No. 16, 2001, pp. 192-198. doi:10.1038/84643
[11] S. J. Mandriota, et al., “Vascular Endothelial Growth Factor-C Mediated Lymphangiogenesis Promotes Tumour Metastasis,” The EMBO Journal, Vol. 72, No. 20, 2001, pp. 672-682. doi:10.1093/emboj/20.4.672
[12] Y. He, et al., “Suppression of Tumour Lymphangiogenesis and Lymph Node Metastasis by Blocking Vascular Endothelial Growth Factor Receptor 3 Signaling,” Journal of the National Cancer Institute, Vol. 94, No. 11, 2002, pp. 819-825. doi:10.1093/jnci/94.11.819
[13] S. Breiteneder-Geleff, et al., “Angiosarcomas Express Mixed Endothelial Phenotypes of Blood and Lymphatic Capillaries: Podoplanin as a Specific Marker for Lymphatic Endothelium,” American Journal of Pathology, Vol. 154, 1999, pp. 385-394. doi:10.1016/S0002-9440(10)65285-6
[14] M. Schmelz and W. W. Franke, “Complexus Adhaerentes, a New Group of Desmoplakin-Containing Junctions in Endothelial Cells: The Syndesmos Connecting Retothelial Cells of Lymph Nodes,” European Journal of Cell Biology, Vol. 61, No. 2, 2005, pp. 274-289.
[15] J. T. Wigle and G. Oliver, “Prox1 Function Is Required for the Development of the Murine Lymphatic System,” Cell, Vol. 98, No. 2, 1999, pp. 769-778. doi:10.1016/S0092-8674(00)81511-1
[16] D. Massi, et al., “Tumour Lymphangiogenesis Is a Possible Predictor of Sentinel Lymph Node Status in Cutaneous Melanoma: A Case-Control Study,” Journal of Clinical Pathology, Vol. 59, No. 2, 2006, pp. 166-173. doi:10.1136/jcp.2005.028431
[17] Y. Miyata, et al., “Lymphangiogenesis and Angiogenesis in Bladder Cancer: Prognostic Implications and Regulation by Vascular Endothelial Growth Factors-A, -C, and -D,” Clinical Cancer Research, Vol. 12, 2006, pp. 800-806. doi:10.1158/1078-0432.CCR-05-1284
[18] H. J. Kahn and A. Marks, “A New Monoclonal Antibody, D2-40, for Detection of Lymphatic Invasion in Primary Tumours,” Laboratory Investigation, Vol. 82, 2002, pp. 1255-1257.
[19] Marinho VF, et al., “Lymph Vascular Invasion in Invasive Mammary Carcinomas Identified by the Endothelial Lymphatic Marker D2-40 Is Associated with Other Indicators of Poor Prognosis,” BMC Cancer, Vol. 8, 2008, pp. 64-68. doi:10.1186/1471-2407-8-64
[20] S. F. Schoppmann, et al., “Prognostic Value of Lymphangiogenesis and Iymphovascular Invasion in Invasive Breart Cancer,” Annals of Surgery, Vol. 240, No. 2, 2004, pp. 306-312. doi:10.1097/01.sla.0000133355.48672.22
[21] X. D. Xie, et al., “Relation of Lymphatic Microvessel Density Detected by Monoclonal Antibody D2-40 with VEGF-C Expression in Breast Cancer,” Zhonghua Zhong Liu Za Zhi, Vol. 30, No. 5, 2008, pp. 356-360.
[22] S. D. Nathanson, “Insights into the Mechanisms of Lymph Node Metastasis,” Cancer, Vol. 98, No. 2, 2003, pp. 413-423. doi:10.1002/cncr.11464
[23] G. Gurleyik, et al., “Lymphovascular Invasion, as a Prognostic Marker in Patients with Invasive Breast Cancer,” Acta Chirurgica Belgica, Vol. 107, No. 3, 2007, pp. 284-287.
[24] R. Jagsi, et al., “Locoregional Recurrence Rates and Prognostic Factors for Failure in Node-Negative Patients Treated with Mastectomy: Implications for Postmastectomy Radiation,” International Journal of Radiation Oncology, Biology, Physics, Vol. 62, No. 4, 2005, pp. 1035-1039. doi:10.1016/j.ijrobp.2004.12.014
[25] B. Kuru, et al., “Prognostic Factors Affecting Survival and Disease-Free Survival in Lymph Nodenegative Breast Carcinomas,” Journal of Surgical Oncology, Vol. 83, 2003, pp. 167-172. doi:10.1002/jso.10264
[26] S. D. Nathanson, et al., “Sentinel Lymph Node Metastasis in Experimental Melanoma: Relationships among Primary Tumour Size, Lymphatic Vessel Diameter and 99mTclabeled Human Serum Albumin Clearance,” Annals of Surgical Oncology, Vol. 4, No. 2, 1997, pp. 161-168. doi:10.1007/BF02303800

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.